Evidence map›Paper›PMID 37027803›Full record

ArticleAnesthesiology2023

Hemostatic In Vitro Properties of Novel Plasma Supernatants Produced from Late-storage Low-titer Type O Whole Blood.

Emily P Mihalko, Amudan J Srinivasan, Katelin C Rahn, Jansen N Seheult, Philip C Spinella, Andrew P Cap, Darrell J Triulzi, Mark H Yazer, Matthew D Neal, Susan M Shea

Open access · greenAbstract read
In one paragraph

Article in Anesthesiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Emily P MihalkoTrauma and Transfusion Medicine Research Center, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0001-9580-1078
Amudan J SrinivasanTrauma and Transfusion Medicine Research Center, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Katelin C RahnTrauma and Transfusion Medicine Research Center, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Jansen N SeheultDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Philip C SpinellaTrauma and Transfusion Medicine Research Center, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Critical Care, University of Pittsburgh, Pittsburgh, Pennsylvania.
Andrew P CapUnited States Army Institute of Surgical Research, JBSA-Fort Sam Houston, Texas.
Darrell J TriulziDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Mark H YazerDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Matthew D NealTrauma and Transfusion Medicine Research Center, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Critical Care, University of Pittsburgh, Pittsburgh, Pennsylvania.
Susan M SheaTrauma and Transfusion Medicine Research Center, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0003-3756-2747
University of Pittsburgh · USUniversity of Pittsburgh Medical Center · USMayo Clinic · USUnited States Army Institute of Surgical Research · US

Funding

TRAINING IN TRAUMA AND SEPSIS RESEARCHT32GM008516 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TIMOTHY R BILLIAR · 1994 to 2026
$9.4M
Mechanistic Elucidation and Targeted Therapy of Platelet Dysfunction After TraumaR35GM119526 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEAL, MATTHEW D · 2016 to 2025
$3.9M
Using Microfluidics to Identify Mechanisms of Platelet Dysfunction and Assess Therapeutic Efficacy in Traumatic HemorrhageK25HL161401 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Susan Marguerite Shea · 2022 to 2026
$643k
NHLBI NIH HHS K25 HL161401NIGMS NIH HHS R35 GM119526NIGMS NIH HHS T32 GM008516
6 · The paper itself

Abstract

backgroundThe use of low-titer group O whole blood is increasing. To reduce wastage, unused units can be converted to packed red blood cells. Supernatant is currently discarded post-conversion; however, it could be a valuable transfusable product. The aim of this study was to evaluate supernatant prepared from late-storage low-titer group O whole blood being converted to red blood cells, hypothesizing it will have higher hemostatic activity compared to fresh never-frozen liquid plasma.

methodsLow-titer group O whole blood supernatant (n = 12) prepared on storage day 15 was tested on days 15, 21, and 26 and liquid plasma (n = 12) on 3, 15, 21, and 26. Same-day assays included cell counts, rotational thromboelastometry, and thrombin generation. Centrifuged plasma from units was banked for microparticle characterization, conventional coagulation, clot structure, hemoglobin, and additional thrombin generation assays.

resultsLow-titer group O whole blood supernatant contained more residual platelets and microparticles compared to liquid plasma. At day 15, low-titer group O whole blood supernatant elicited a faster intrinsic clotting time compared to liquid plasma (257 ± 41 vs. 299 ± 36 s, P = 0.044), and increased clot firmness (49 ± 9 vs. 28 ± 5 mm, P < 0.0001). Low-titer group O whole blood supernatant showed more significant thrombin generation compared to liquid plasma (day 15 endogenous thrombin potential 1,071 ± 315 vs. 285 ± 221 nM·min, P < 0.0001). Flow cytometry demonstrated low-titer group O whole blood supernatant contained significantly more phosphatidylserine and CD41+ microparticles. However, thrombin generation in isolated plasma suggested residual platelets in low-titer group O whole blood supernatant were a greater contributor than microparticles. Additionally, low-titer group O whole blood supernatant and liquid plasma showed no difference in clot structure, despite higher CD61+ microparticle presence.

conclusionsPlasma supernatant produced from late-storage low-titer group O whole blood shows comparable, if not enhanced, in vitro hemostatic efficacy to liquid plasma. EDITOR’S PERSPECTIVE:

Indexed as

HemostaticsThrombinBlood CoagulationBlood PlateletsHemostasisThrombelastographyHemostaticsThrombin

Identifiers

PMID37027803
PMCPMC10247395
OpenAlexW4362705112

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.